International Comparisons of Prices and Volumes in Health Care among OECD Countries

Manfred HUBER,
European Center for Social Welfare Policy and Research

December 18, 2006

For additional information, please contact:

Author name(s) : Manfred HUBER
Author address(es) : European Center for Social Welfare Policy and Research, Berggasse 17, Vienna, AUSTRIA
Author E-mail(s) : huber@euro.centre.org
Author fax(es) : +43 1 319 45 05 19
Author telephone(s) : +43 1 319 45 05 35
Abstract

Data on volumes and prices in health care are essential to complement health accounts for the purpose of international comparisons of activities, output and productivity. Different data sets are needed to track changes over time, and to explain differences across countries at any point in time. The absence of data on comparative price levels in international data collections has been identified as an important gap in the evidence for health policy analysis and comparative research. Moreover, improving PPPs for health expenditure is an important sub-task for the overall improvement of the aggregate PPP comparison exercise.

This paper both contributes to clarifying the methodological foundation of comparative price-volume measurement in health care and proposes changes in the variable list to cover health in the Eurostat-OECD Purchasing Power Parity (PPP) exercise, which itself serves as a methodological point of reference.

The methodological parts analyse among others the statistical challenges posed by the existence of “quasi markets” in health care that often do not fit well in the dichotomy of market versus non-market production. Moreover they comment on the role of quality adjustments for volume measurement.

Among the newly proposed variables for data collection is a set of case vignettes for comparison of hospital (inpatient) production. These include both elective and emergency cases. The paper recommends a consolidated data set for comparisons of volumes and prices in health care (total spending and its sub-components), comprising both newly developed indicators and data already collected under the Eurostat-OECD PPP exercise. The paper concludes with next steps for advancing the project of improved PPPs for health care.
# Table of contents

Abstract ................................................................................................................................................. 2

1. Introduction and Background ........................................................................................................... 5

2. International comparisons of real health expenditure, prices and volume measures: fields of applications ........................................................................................................................................... 6
    Direct volume comparison of service consumption ......................................................................... 7
    Indirect comparisons of relative price levels at basic heading level ........................................... 7
    The need for health-specific purchasing power parities ................................................................. 7
    Analysis based on H-PPPs and its components .............................................................................. 8
    Limitations of price and volume measures ..................................................................................... 8

3. The basic framework for price and output measurement for international comparisons ................. 9
    The concept of volumes of health care services: activities, output, and outcome ......................... 9
    The concept of unit prices for comparing health care services ...................................................... 10
    Measuring transaction prices .......................................................................................................... 11
    Source: draft Eurostat-OECD PPPs manual, Chapter 2, 2.17 ......................................................... 12
    The distinction between market and non-market production in health care ................................... 12
    Where to start from: comparing prices or volumes (quantities)? .................................................. 13

4. Classification principles for PPPs in health ...................................................................................... 15
    The structure of health expenditures: the selection of “basic headings” ....................................... 15
    Defining expenditure categories based on NA categories or SHA-based health accounts? .............. 17
    Advantages of using expenditure categories of SHA-based health accounts ................................ 17
    Limitations of expenditure categories of SHA-based health accounts ......................................... 18

5. Consolidating and expanding the variable list of the Eurostat-OECD PPP project ......................... 19
    Choosing the measurement unit: input versus output and outcomes .......................................... 19
    Comments and proposals on the list of health items in the Eurostat-OECD PPP project ................. 19
    11.06.11.0 Pharmaceutical products [COICOP 06.1.1] ................................................................. 19
    11.06.13.0 Therapeutic appliances and equipment [COICOP 06.1.3] ......................................... 20
    11.06.21.0 Medical Services [COICOP 06.2.1] ............................................................................ 20
    11.06.22.0 Dental services [COICOP 06.2.2] ............................................................................... 22
    11.06.23.0 Paramedical services [COICOP 06.2.3] .................................................................... 22
    11.06.31.0 Hospital services [COICOP 06.3.0] ......................................................................... 23

6. A proposal for an improved questionnaire on hospital services ..................................................... 24
    How many items should the list of hospital cases include? .......................................................... 24
    Which items should be included? .................................................................................................. 25
    How detailed should case-descriptions be? .................................................................................... 26
    A proposed shortlist ....................................................................................................................... 27
    Description of case vignettes ......................................................................................................... 28
    A note on the sampling design ....................................................................................................... 34
    The role of DRG systems in mapping (hospital) inpatient services .............................................. 35

7. Accounting for differences in the quality of services .................................................................... 38
    Choosing homogeneous groups of services with distinct difference in quality ......................... 40
    Quality adjustment with measures of health gains? ....................................................................... 40
    Recommendations on quality adjustments for H-PPPs ............................................................... 42
    Recommendations 3. The role of quality adjustment .................................................................... 42
8. Conclusions ........................................................................................................................................... 43
   Division of labour and resources required .............................................................................................. 43
   Proposal for a sequence of tasks to carry work on H-PPPs forward .......................................................... 43
   Refinements of SHA-based health accounts and expenditure estimates ................................................. 44
   The market/non-market boundary ............................................................................................................. 44
References .................................................................................................................................................... 46
Annex 1. The Health BASKET project ........................................................................................................ 53
Annex 2. International Shortlist for Hospital Morbidity Tabulation (ISHMT) ................................................ 54

Boxes

Box 1. A note on basic terminology: Price, volume, quantity and value measures .............................. 6
Box 2. Defining transaction prices for joint public-private payment ....................................................... 11
Box 3. Differences between the H-PPP project and the ARD project ..................................................... 24
Box 4. International Shortlist for Hospital Morbidity Tabulation (ISHMT) ........................................... 26
Box 5. Examples of regional variations in unit costs of medical care ....................................................... 35
Box 6. Atkinson recommendation: Principle B (see para 4.24) ............................................................... 41

Tables

Table 1. Four estimation methods and their data requirements .............................................................. 14
Table 2. Classification of basic headings for “Health” in the Eurostat-OECD 2002 PPP estimates ...................... 15
Table 3. Classification of individual consumption expenditure by private households ....................... 16
Table 4. A proposed shortlist of inpatient case vignettes ......................................................................... 28

Figures

Figure 1. Weak correlation between birth rates and discharge statistics raises a number of questions ................................................................................................................................................... 33
Figure 2. The “family tree” of inpatient classification systems ................................................................. 36
Figure 3. Typical paths in establishing DRG systems ............................................................................... 37
Figure 4. Countries do not perform consistently better on several quality indicators ......................... 39
Figure 5. Correlation of quality dimensions is often weak ........................................................................ 39
1. Introduction and Background

Data on volumes and prices in health care are essential to complement health accounts for the purpose of international comparisons of activities, output and productivity. Different data sets, concepts and methodologies are needed to track changes over time, and to explain differences across countries at any point in time.

The absence of data on comparative price levels in international data collections has been identified as an important gap in the evidence for health policy analysis and comparative research. In the absence of a common currency denomination, specific to health care services, there is much uncertainty about how to interpret differences in health care spending between countries. To which extent are different spending levels due to real differences in the activity level or volume of services – with or without adjustment for differences in quality of care and outcomes – or to variations in price levels? These questions need to be addressed at various levels of aggregation.

Moreover, market and non-market production of health care services is an important component of overall GDP and therefore a significant source of uncertainty for the overall PPP estimates in the International Comparison Project (ICP).

Chapter 7 in the OECD manual A System of Health Accounts (SHA) discusses methodological issues of price and volume measurement in health care and sketches a proposed framework to improve price indices for medical services in national health accounts in order to make them better suitable for health policy analysis. It refers briefly to the need for improving comparisons between countries and to the health component in purchasing power parities but does not further elaborate on this task. This paper outlines a strategy to do so.

Progress has been made over the last ten years in data quality and international availability of indicators at the semi-aggregate level of health care services which potentially could be used to derive indicators for tracking national differences in aggregate health care price levels. The OECD Secretariat has currently the most comprehensive data set for international comparisons at hand, which already includes data that can be tested for their potential to analyse differences in volumes of services between countries. Among these are: OECD Health Data, SHA-based health accounts, and the OECD Health Care Quality Indicator Project. Moreover a number of research projects have been funded on European level to foster comparison of health care systems, notably under the 5th and 6th framework programmes of research of the European Union.

This paper in addition explores ways to improve the health expenditure part of the OECD-Eurostat purchasing power parity project with a view to propose a number of changes for future data collections after the end of the current 2000-2006 round of data collection and estimation.

This paper builds on a recent paper (OECD, 2005a) that was discussed at the Meeting of Health Accounts Experts and Correspondents for Health Expenditure Data, on 29-30 September 2005. The 2005 paper had a focus on clarifying

methodological issues of comparative price-volume measurement in health care more generally. This paper outlines concrete steps towards expanding the variable list that might be used in future rounds of the Eurostat-OECD program of PPP calculations and to move to output measurement of hospital inpatient services.

The paper therefore serves as a contribution to the reflections in the framework of the project of reforming the Eurostat-OECD program of PPP calculations, which is led by a common OECD-Eurostat Task Force, the agreement of which will be needed for any reform. The current round of PPP collection for the health sector will be finalised in 2006. The scope of the reform is therefore 2008 (the next round of health PPP data collection).

A secondary goal is to provide comments on the wider agenda of health accounting, such as on how to better reconcile the ways health care is classified in National Accounts and in the framework of the System of Health Accounts.

Box 1. A note on basic terminology: Price, volume, quantity and value measures

The basis of defining comparative price levels is the identity:

\[ \text{Expenditure} = \text{price} \times \text{volume} \]

A number of other terms frequently used in this context are:

**Value**: a synonym for expenditure, (System of National Accounts)

**(PPP) Purchasing power parity**: A relative price which measures the number of units of country B’s currency that are needed in country B to purchase the same quantity of an individual good or service as 1 unit of country A’s currency will purchase in country A.

**Output**: often used as synonym for volume of output of a well-defined bundle of goods or services;

**Quantity**: quantities are defined as units for homogenous, individual goods or services (volumes, in contrast, are weighted averages of quantities adjusted for quality if needed; in health research, both terms are sometimes used interchangeably); quantities are additive only for a single homogenous product.

**Real expenditure**: in international comparisons expenditure “that have been converted to a common currency and value at a uniform price level using PPPs” (either PPPs for GDP or health-specific PPPs). “Expenditures so converted are valued at international prices and reflect only volume differences between countries”.

**Volume**: (expenditure) weighted average of (all) quantities of individual products (individual output).

Source: adapted from: SNA93, Chapter 16 on “Price and volume measures”; OECD SNA93 glossary; and the Glossary of the Eurostat-OECD PPP manual.

2. International comparisons of real health expenditure, prices and volume measures: fields of applications

Price and volume measures for international comparisons on health care are of interest at different levels of aggregation. Because estimation methods become more and more complex during aggregation, and less transparent for the potential users, it is essential to aim at testing and publishing indicators at each level of aggregation together with the original input data. This paper argues that the important investment of resources in the indicators needed to improve H-PPPs can arguably be justified only if these also become available for the health care research community as original data. This is also dictated by the central role that health statisticians and health
researchers in OECD countries will have to play in designing the data collection and in conducting pilot collections, order to ensure comparable, good quality data.

**Direct volume comparison of service consumption**

Health expenditure on a basic level of aggregation, and sets of corresponding output indicators (on treatment episodes, regulated prices and relative costs) are the basic building blocks of composite measures for comparing price levels between countries. Making volume (output) and activity data (e.g., number of doctors’ consultations or surgical procedures of certain types) “fit together” on this lowest aggregation level is an important objective in itself. It is at this level that the basic data quality requirements have to be met. These comparisons will then provide alternative ways of looking at comparative activity levels, which are frequently used in international comparisons (e.g., in OECD, 2005, Health at a Glance; the health care resource profiles proposed by Anell and Willis, 2000, or comparative tables presented in the literature: Anderson *et al.*, 2005).

**Indirect comparisons of relative price levels at basic heading level**

Volume or cost/price relatives - that is the ratio of the volumes (or prices) of products in one country to the volume (or prices) of the same product in other countries - can be used for indirect comparisons of relative price-levels at the same levels of aggregation.

In this simplest form of price comparisons, these price relatives show the ratio of the prices in national currencies of the same bundle of good or service in different countries. If divided by exchange rates, they will provide an indicator which is called "comparative price levels" in the Eurostat-OECD PPP. This indicator provides a measure of the differences in price levels between countries by indicating for a given product groups the number of units of a common currency needed to buy the same volume of the product group or aggregate in each country (Eurostat-OECD, 2005).

**The need for health-specific purchasing power parities**

International comparisons of per capita health expenditure have to be made in a common currency unit. For this purpose, nominal expenditure in national currency are usually converted to US dollars (USD) in purchasing power parities for gross domestic product (Eurostat disseminates in pseudo-Euros). Purchasing power parities (PPP) are rates of currency conversion estimated to account for price differences between countries.

Health expenditure per capita converted in USD PPPs are in fact among the most frequently quoted indicators for international comparisons, and are usually presented in the form of a country ranking. This is done for total expenditure on health and for its sub-components (e.g., OECD, 2005, Health at a Glance). For international comparisons, this method of PPP conversion is preferred over the use of exchange rates, because exchange rates do not directly measure relative price levels in countries. In addition, exchange rates, in fluctuating widely, do not always follow closely changes in relative prices over time.
Another measure would be per capita expenditure converted by using sector specific PPPs. Conceptually, this would lead to estimates that by their definition were true measures for the relative volume of health services between countries. It can be expected that, if measured properly, these estimates, and any country ranking based on them might deviate in characteristic ways from indicators based on conversion by using economy-wide PPPs. A main reason for this is that only a small fraction of health services enter international trade, similar to other service industries. As a result, differences in price levels in service industries have been found to be larger than economy-wide price levels. This is in particular relevant when countries are compared that differ widely in their income level (Tandon, 2002a, p.3, and Balassa, 1964).

A broad literature now exists on the determinants of per-capita spending on health in international comparison, where expenditures are usually expressed in PPP for GDP. It can be expected that the results from many of these studies will change substantially if health expenditure were expressed in health specific PPPs (H-PPPs). It has long been recognised that analysis based on these indicators is not robust against the choice of conversion factors (see Gerdtham and Jonsson, 1991). The choice of conversion factors to account for price differentials was also at the core of recent debates on the validity of conclusions from binary comparisons of health care systems (see Feachem et al., 2002, comparing the U.K NHS with Kaiser Permanente, California).

Analysis based on H-PPPs and its components

The ultimate goal of investing in the project outlined in the paper is to substantially improve volume measures and comparative prices for health care for use in the analysis of healthcare performance. It is, however, important to keep in mind that the indicators derived from this project in themselves are not performance measures.

Differences in the price level, e.g., can be due to differences in factor input prices, differences in productivity, or quality of services. It is only with secondary analysis that volume and price measures can be brought to life as performance measures. The study of determinants for differences in price levels between countries would in fact be one of the most important applications of the indicators to be estimated under this project. Furthermore, these would be essential building blocks for productivity comparisons if the project would be extended to collect indicators on real inputs to the production of health care services.

Limitations of price and volume measures

The Eurostat-OECD PPP publications distinguish between recommended uses; uses with limitations; and not recommended uses of PPPs and its derived indicators (Eurostat-OECD, 2005, 2002 benchmark estimate, p.16). Some of these limitations and “health warnings” for the resulting numbers should also be kept in mind when using any refined H-PPPs and its component measures:

- Among the recommended uses are: comparing total volumes; grouping countries by expenditure per capita; estimating (total) (labour) productivity;
• “Uses with limitations”: estimating changes in time of the above indicators (comparability over time poses additional data challenges, requiring the stability of the indicators selected, their availability for aggregation, etc.);

• “Not recommended uses”: this includes establishing strict rankings of countries (e.g., for expenditure per capita).

The Eurostat-OECD publication also warns that the interpretation of component measures for disaggregated price comparisons have to be done with caution, because these are more volatile and error-prone than comparisons at the aggregate level. The project of H-PPPs hopefully will provide more robust estimates for use at the disaggregated level. In fact, from the point of view of the international health care research community, this can be considered their main or primary purpose, with the more aggregate measure of H-PPPs for total expenditure and GDP being a secondary goal, not the primary one.

In addition, as averages across regions and population groups these measures do not reveal any information about the distribution of health care consumption, which is critical for establishing links to outcomes, such as population health gains.

3. The basic framework for price and output measurement for international comparisons

This chapter presents a proposal for price and volume indicators for health care. It presents a toolbox of working definitions from core concepts, which experts in purchasing power parity and health economists have designed for price and volume measurement. There has been much progress in methodology recently that has helped to clarify what is measured in volume comparisons (such as the notion of output in terms of whole treatment versus isolated activities), and how to define transaction prices in health care.

However, there are still fundamental differences in the approaches currently used, or proposed for making progress in the health field. Among the main methodological decisions to be made are:

• The structure of a list of “basic headings” for comparisons;

• The definition of units of measurement;

• The extent to which differences in quality in health care should explicitly be accounted for.

The concept of volumes of health care services: activities, output, and outcome

It is important to distinguish these concepts (Dawson et al., 2004, Cutler and Bernd, 2001).
**Activities** are surgical and other medical procedures, consultations with a specialist; lab tests. In short, many of the items on fee-for-service lists fall under this concept.

There is now broad consensus that the most appropriate concept for defining health care outputs is episodes of treatment (often requiring a bundle of activities). Examples are treatment of acute illness or disease, or of chronic disease, such as diabetes, cancer, heart disease. The definition of health output for national price indices in health care in the Eurostat handbook of price and volume measurements states:

> “Health output is the quantity of health care received by patients, adjusted to allow for the qualities of service provided, for each type of health care. The quantities should be weighted together using data on the costs or prices of the health care provided. The quantity of health care received by patients should be measured in terms of complete treatments.” (Eurostat, 2001, p.117)

The term of outcomes refers to a multi-dimensional concept of (positively or negatively expressed) characteristics of output, such as health changes, “responsiveness” of services to peoples non-health expectations (e.g., no waiting time, other convenience of access, quality of facilities, and amenities in hospitals or nursing homes). There are several possibilities for valuation of changes in health states measured, such as Quality Adjusted Life Years (QALYs).

For non-health related outcomes such as reduced waiting times one could think of other estimates. An important quality measure would, for example, look into the reduction that has occurred in average time of sick-leave from work for common hospital inpatient treatments, or for day surgery.

The example of reduced sick-leave also illustrates that there is more to health care outcome than individual health gains (or reduced illness). Universal health care provision is an important factor contributing to social cohesion and the related feelings of security themselves can be beneficial for population health.

The term of volumes, as used in this paper, ideally refers to volumes of outputs, where outputs are defined as above, not outcomes.

**The concept of unit prices for comparing health care services**

The concept of prices is linked to the concept of actual market transactions for well-defined health care outputs, where, in a market system (or in a well-functioning system of quasi-markets with collectively or individually negotiated prices and tariffs), the relative prices of different goods and services are expected to reflect both their relative costs of production and their relative utilities to purchasers (SNA93, Chapter 16).

For health care services, there are a number of reasons, why this concept of market transaction has limits, for both market and quasi-markets (the later with administrated prices) of health care. First, there are typically many providers that operate both in the publicly funded (non-profit) and in the private for-profit sector of
health care markets. Their relative “prices” in the public and private sector (private fees versus regulated remuneration or tariffs for public patients) may not correspond well to the relative cost of production that they occur in both segments.

In many cases, the private “business” prices may be too high to be justified by the real differences in treatments compared to the public fees for similar types of treatment. On the other hand, providers may be able to accept fees (or salaries) in the public system that would not compensate them fully, provided that their (public) workplace allows them to access private clientele.

Perhaps more problematic, for health care services, is the correct interpretation of the concept of “relative utilities to purchases”\(^2\). Users of services will in many cases have only a limited knowledge of the benefits that they can expect from alternative treatments. This is both a problem of asymmetric information, but – perhaps more importantly – can also reflect a general lack of knowledge of both the medical profession and of service users about the effectiveness of many common treatment choices, not only in primary care, but also for very specialised services, such as the use of the latest generation of stents in treating acute myocardial infarction.

Measuring transaction prices

Leaving aside the qualifications on the “market-signals” of health care prices just made in the section above, it is important that for joint public-privately paid services, both components of the purchase are brought together (added up, if paid for separately) in order to arrive at transaction prices. This means that the amount covered by a public programme and the cost-sharing paid for by private households have to be added up to arrive at the correct transaction price. The following explanation on transaction prices in this respect is taken from the Eurostat-OECD PPPs manual.

**Box 2. Defining transaction prices for joint public-private payment**

“For example, in many countries, payments for medical services are shared between households and government. Either households pay the medical practitioner in full and subsequently receive the government’s share as a reimbursement or both households and government pay their share to the medical practitioner directly. Whatever the system, in the national accounts, the amounts actually paid by households (based on prices paid less any reimbursements) are recorded under household expenditure and the amounts actually paid by government (based on reimbursements paid to households and/or payments made directly to medical practitioners) are recorded under government expenditure. If households actually pay 20 euros per consultation and government actually pays 80 euros per consultation and 100 consultations take place, 2000 euros would be recorded under household expenditure and 8000 euros under government expenditure. To obtain the correct volume it is necessary to divide both household expenditure and government expenditure by the total or composite price of 100 euros ([2000 / 100] + [8000 / 100] = 100 consultations). Otherwise, if the expenditures are divided by the prices households and government actually paid, that is by 20 and 80 euros respectively, there would be double counting ([2000 / 20] + [8000 / 80] = 200 consultations). To

---

\(^2\) See also the remark in the quality chapter on placebo-effects.
avoid this, countries participating in Eurostat-OECD comparisons are required to report total or composite prices for all final expenditures to which they apply.”

Source: draft Eurostat-OECD PPPs manual, Chapter 2, 2.17

The distinction between market and non-market production in health care

For health care services, the concept of purchasers’ prices of actual market transactions often does not apply very well. This is obviously the case for non-market services of health care. The OECD-Eurostat PPP estimates, and their global version, the International Comparison Programme (ICP) draw a clear boundary between market and non-market production (and expenditure) in health. Both have in the current and past rounds of the ICP programme been treated in different ways and have fundamentally different data requirements for international price and volume comparisons.

In spite of its fundamental nature for price-volume comparisons, the SNA93 and the PPP manual do not discuss the criteria for this distinction in any detail. The main criteria for classifying production as market product is always that output is sold at “economically significant prices”.

In the ICP programme, the actual estimations rely on national practices of individual countries. Therefore, “labels” of “basic headings” (and the subsequent prices or costs collections) tend to automatically classify all government own production of publicly funded health care as non-market production, irrespective of the way in which an internal market between public providers and third-party public funds might be organised, i.e. also for cases where transfer prices in the form of tariffs or fee-for-services are subject to complex negotiations between different public authorities and a certain degree of competition between providers, and/or financing authorities is now in place in many cases.

This shortcut of estimating all government production of public health care services as non-market production (as sum of its cost components) seems not to be dictated by the spirit of the SNA93. It is also remarkable in this respect that National Accounts in some countries with partially publicly organised health care provision do not use the market/non-market distinction (Australia, Japan, Korea).

One of the innovations of SNA93 over its predecessor, the 1968 SNA, is in fact that the way market and non-market is defined in SNA93 “makes it possible to include all heavily subsidized public enterprises as market producers provided their prices are considered economically significant from the point of view of cost and demand” (SNA93, Annex I, 6.52). For the case of health care, health economists label these cases as “internal markets” or “quasi markets” in health care. These regulated markets of health care services have over the past 20 years indeed become the predominant model for the organisation and regulation of publicly funded health care in OECD countries and in many non-OECD middle-income countries as well.

Health policy debates and reform in OECD and a number of middle-income countries have been strongly influenced by a trend towards ‘marketisation’, a label
used for a range of different models of markets mechanisms in publicly funded health
care (Mills and Broomberg, 1998). This policy trend has also been analysed by
observers in the context of a broader movement of new public sector management that
aims at improving efficiency of public service provision with the help of a range of
private sector mechanisms and management strategies.

Quasi-markets have become the predominant form of organising the
reimbursement of large parts of health care services in many countries. Clarifying the
consequences of this policy trend for the health component in the ICP project will
therefore be of core importance for reforming the health component in the PPP
programme, but will partly depend on moving conventions in national accounts.

These trends in public sector management have so far not left traces in the way
the “market” versus “non-market” boundary is explained or exemplified and finally
applied in the SNA93 or in the PPP manual. In fact, the notion of “quasi-market” is
currently not used in either SNA93 or the 2005 ICP manual, but is in fact used
occasionally in practical guidelines and in the ICP discussion, e.g., OECD, 2000c. In
this context, “quasi-market” and “market production” is used as a common category
distinct from “non-market”. Because quasi-markets in health care are spreading fast in
OECD countries, this paper will argue that this has probably wider implications for
the ICP exercise than is recognised in the current discussion on how to improve the
health component in the ICP project.

“Internal market” or “quasi-market” are labels that are used for a wide range of
organisation of health care delivery and financing. These include examples of
competition both among providers and among public financing funds and the more
common cases of monopsonistic public purchasers that negotiate tariffs and fees for
services with a number of different providers or provider associations, where total
revenues of providers is frequently a mix of “sales” of tariff-based services and other
sources of funding, such as subsidies to compensate for deficits, grants for fixed
capital formation, or for certain additional functions, e.g., for education and training
provided at teaching hospitals.

Eurostat has set up the rule to classify as “market production” industries for
which more than 50% of production is remunerated from (administered) prices. Under this rule a number of health care sub-sectors of public providers of health care
have already been (re)classified as “market producers”.

Where to start from: comparing prices or volumes (quantities)?

This section discusses the basic choices available for estimating price/volume
comparisons between countries for health care services. The measurement of real
spending differences on health care services can in principle be based on direct price
level comparisons, or - alternatively – on direct measurement via quantity indicators.
In the absence of market transaction and market prices, input prices are currently used
in the ICP and Eurostat/OECD comparisons. A less frequently used method is the
comparisons of input quantities. The following table summarises the different
methods from the perspective of their data requirements. Consequently, four possible
methods have been proposed for international comparisons: the input price approach;
the input quantity approach; the output price method; and the output quantity method.
Table 1. Four estimation methods and their data requirements

<table>
<thead>
<tr>
<th>Input</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Detailed expenditures on inputs (labour and intermediate inputs);</td>
<td>Detailed expenditures on inputs (labour and intermediate inputs);</td>
</tr>
<tr>
<td></td>
<td>average salary data of selected occupations (1)</td>
<td>numbers of workers in selected occupations</td>
</tr>
<tr>
<td>Output</td>
<td>Detailed set of unit prices for market prices; alternatively</td>
<td>Detailed list of selected services; representative mapping to expenditure</td>
</tr>
<tr>
<td></td>
<td>imputed prices of selected services (cost estimates) for non-</td>
<td>categories</td>
</tr>
<tr>
<td></td>
<td>market services</td>
<td></td>
</tr>
</tbody>
</table>

Source: adapted from Tandon et al. (2002, Table 4)

(1) The Eurostat-OECD comparisons collect for this purpose data on 17 input items, among which are 3 salary items.

For most components of GDP, prices are usually considered to be easier to observe for the purpose of PPP estimates than quantities and to have a smaller variability than direct measures of relative quantities (Eurostat-OECD, 2005). For the international comparison of health care services, however, there are many obstacles towards defining and measuring unit prices across countries, as outlined above.

For non-market health care services, the Eurostat-OECD comparisons use for this reason the input-price approach. Obviously, this approach cannot take into account labour productivity differences between countries. In principle, adjustments could be made using differences (rations) in employee compensation rates in market services. However, these adjustments are highly speculative, in the absence of real evidence on productivity differences in health care services between countries. Another adjustment would be to attach different weighting schemes to the occupational groups used in the input-price estimates.

None of these refinements seem to result in robust estimates for price levels in health care services that would warrant meaningful results for the kind of analysis sketched in the first chapter. The input cost approach has therefore been met with much scepticism in recent years (see e.g., the review of Ian Castle, 1997).

Another alternative approach to the input-price method for non-market services would be to calculate hypothetical output prices based on public reimbursement mechanisms. There, the problem is that observable “unit prices” for health services frequently are not closely related to production cost. Comparability problems also stem from the fact that cost of investment (important for the capital consumption component of cost estimates), may be covered by a dual payment method, with fee-payments only covering part of these cost. The estimation problem is aggravated in situations when provider groups (most prominently hospitals) run substantial deficits, covered by state aid.
Finally, it has been proposed to use as proxies for “unit prices” of non-market production the prices observed from parallel markets of privately financed health care services. But again, the observed biases from this estimation method have been found to be too important as to lead to estimates usable for the analytical purposes outlined above.

For all these reasons, only direct price or quantity comparisons will yield meaningful estimations for health policy analysis. Another advantage of this approach is that secondary data sources, mainly from administrative sources, which are already used in international comparisons of health care, could be used, if refined for the purposes of this project.

4. Classification principles for PPPs in health

This section discusses the fundamental classification principles for PPPs in health care and the ways these are currently applied in the OECD-Eurostat PPP project. This paper closely follows the classification proposed by the central statistical system of the SNA93 and its accompanying classification. In these classifications, actual final consumption of health services and goods is structured in a relatively simple and traditional way that will also be followed in this paper. A basic distinction is made between services that correspond to market versus non-market production.

*The structure of health expenditures: the selection of “basic headings”*

Table 2 shows the basic headings that have been used for “health” in the Eurostat-OECD 2000 estimation round.

**Table 2. Classification of basic headings for “Health” in the Eurostat-OECD 2002 PPP estimates**

<table>
<thead>
<tr>
<th>Main aggregates Categories</th>
<th>Categories</th>
<th>Groups</th>
<th>Classes</th>
<th>Basic headings</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00 Individual consumption expenditure by households</td>
<td></td>
<td></td>
<td></td>
<td>148</td>
</tr>
<tr>
<td>- .06 Health</td>
<td>13</td>
<td>48</td>
<td>109</td>
<td>148</td>
</tr>
<tr>
<td>12.00 Individual consumption expenditure by NPISHs</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>- .02 Health</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>13.00 Individual consumption expenditure by government</td>
<td></td>
<td></td>
<td></td>
<td>29</td>
</tr>
<tr>
<td>- .02 Health</td>
<td>5</td>
<td>7</td>
<td>16</td>
<td>29</td>
</tr>
<tr>
<td>14.00 Collective consumption expenditure by government</td>
<td></td>
<td></td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>- .02 Health</td>
<td>1</td>
<td>2</td>
<td>7</td>
<td>17</td>
</tr>
<tr>
<td>15.00 Gross fixed capital formation</td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td>16.00 Change in inventories and acquisitions less disposals of valuables</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>17.00 Balance of exports and imports</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Health</td>
<td>3</td>
<td>6</td>
<td>15</td>
<td>25</td>
</tr>
<tr>
<td>GDP</td>
<td>31</td>
<td>71</td>
<td>152</td>
<td>226</td>
</tr>
</tbody>
</table>

Source: Eurostat-OECD (2005)
The seven basic headings under the category “individual consumption expenditure by households” are detailed in Table 3.

Table 3. Classification of individual consumption expenditure by private households

<table>
<thead>
<tr>
<th>11.06.10.0</th>
<th>MEDICAL PRODUCTS, APPLIANCES AND EQUIPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.06.11.0</td>
<td>Pharmaceutical products [COICOP 06.1.1]</td>
</tr>
<tr>
<td>11.06.12.0</td>
<td>Other medical products [COICOP 06.1.2]</td>
</tr>
<tr>
<td>11.06.13.0</td>
<td>Therapeutic appliances and equipment [COICOP 06.1.3]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11.06.20.0</th>
<th>OUT-PATIENT SERVICES</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.06.21.0</td>
<td>Medical Services [COICOP 06.2.1]</td>
</tr>
<tr>
<td>11.06.22.0</td>
<td>Dental services [COICOP 06.2.2]</td>
</tr>
<tr>
<td>11.06.23.0</td>
<td>Paramedical services [COICOP 06.2.3]</td>
</tr>
<tr>
<td>11.06.31.0</td>
<td>Hospital services [COICOP 06.3.0]</td>
</tr>
</tbody>
</table>

As a starting point for reflections on how to improve H-PPPs, it is important to note that price and volume information is only collected for the first six items. For hospital services, publicly produced hospital services are used as “reference”, which means that no own estimate is calculated. Publicly produced hospital services are all classified as “non-market” and their international comparison is based on prices for inputs.

A number of additional simplifications underlie the estimation of H-PPPs in the current OECD-Eurostat PPP project:

1. The same prices apply for privately funded medical goods and services (other than hospitals) and publicly reimbursed goods and services that are bought from “market producers”.

2. Health expenditure on non-profit institutions serving households is covered by the input method, for all kinds of services together.

3. There is no separate category in the PPP expenditure classification for public sector non-profit organisations, which play an important role in many countries.

Recommendation 1. Treatment of basic headings in future H-PPP estimates

From this list of simplifications it is obvious how to proceed to improve H-PPPs in the current OECD-Eurostat PPP project:

1. Individual consumption expenditure by government and by non-profit institutions should be compared using an output approach; this is in particular relevant for hospital inpatient services;
(2) Where non-profit institutions serving households and government owned producers operate on the same quasi-markets, these non-profit organisations should be treated for price-volume comparisons of their publicly funded health care services in the same way as government entities;

(3) It would be worth to reconsider if the same price comparisons should be done for privately and publicly reimbursed goods and services bought from market producers, knowing that private and public tariffs can differ substantially. But this later point should probably only be tackled after the larger part of government produced health care expenditure on services has been moved to an output method.

Defining expenditure categories based on NA categories or SHA-based health accounts?

Advantages of using expenditure categories of SHA-based health accounts

Because the project of comparable price levels starts with the definition of components of final demand on the expenditure side of national health accounts, any improvements in comparability of these aggregates and in better detail to map activity and price information of modern health care to these expenditure aggregates are vital to improve H-PPPs.

For this purpose, the functional component of the International Classification for Health Accounts (ICHA) provides the basic levels of aggregation for the estimation of comparative aggregates based on SHA-based health accounts. It is a basic principle of the SHA framework that functionally defined expenditure categories lead to better comparable aggregates, in principle. It is on this dimension of health expenditure (the ICHA-HC) that output measures can best be linked for international comparisons in comparative ways. The functional breakdown of SHA-based health accounts provide important splits of a number of health categories in the Central Product Classification (CPC) that are used in National Accounts.

Perhaps most important of these is the split of hospital production in different product categories that correspond to different types of services: inpatient versus outpatient departments, and day-clinics. Modern hospitals have become ever more complex multi-product industries, making it risky to compare them internationally if the simple assumption is used that their main output, namely inpatient services, is representative for their total output.

Using CPC categories as sole classification instrument is also risky because the arguably most dynamic part of health expenditure and activity, which is selective surgery and a number of complex diagnostic procedures that now are routinely done on a day-case basis but in the past would have required a hospital stay. There are a number of CPC categories that are in “competition” for these patients and it is not a valid assumption to assume that this growing expenditure part can be allocated to one CPC category only (as a reasonable approximation). As a result, it would be doubtful how this sizable part of modern health care can be compared across countries, based on CPC categories.
Limitations of expenditure categories of SHA-based health accounts

From the standard tables of the SHA it is clear that these do not allow for distinguishing between market and non-market services. Although the framework of the SHA manual clearly distinguishes between the two for defining expenditure in the same way as this is done in National Accounts, and as a recommendation for the estimation process (SHA, 2000), the SHA manual currently does not ask administrations in member countries to report on this additional breakdown.

The different treatment of market versus non-market production in price comparisons (between NA and SHA) applies both to international comparisons and national comparisons over time. Establishing here a better link between NA and SHA-accounts could therefore be important both for national and international comparative purposes.

Moreover, the SHA standard tables currently do not include the distinction between private cost-sharing and other out-of-pocket expenditure, although this is part of the three-digit level of the ICHA-HF funding (purchasing) component of the health expenditure classification. A separate estimation step is therefore needed if SHA-aggregates are to be directly compared with volumes and (transaction-) prices of health care services, as these combine the public and private price- (and expenditure) component.

Recommendation 2. Steps to reconcile NA estimates with SHA accounts

CPC categories currently used in NA estimates will need refinement to contribute to better international comparability and to the greater analytical power than SHA accounts have achieved. This is especially relevant for the project of reforming H-PPPs.

(1) The main challenge here is the agreement on the needed separation of production in different settings (inpatient, day-care, outpatient and ambulatory) for some CPC categories as this is were much of the dynamic of changes in modern health care systems lies, and corresponding differences between countries that need to become transparent in international comparisons in order to understand differences and communalities. Currently much of modern health care has no natural “home” in the current CPC classification (eg. much of day care).

(2) An adequately revised CPC “for H-PPPs and SHA accounts” section (for the time being) would allow for a close reconciliation of SHA accounts with NA estimates, keeping in mind that the satellite-account nature of SHA allows for a number of departures of defining expenditure, such as the reclassification of occupational care and of care allowances to output.

(3) Correcting for the currently unfortunate asymmetry in the way CPC treats (long-term) home care (as part of health care) versus “social care with accommodation” (it belongs to social services) is a major challenge of this task of overall reconciliation. It should, therefore, have priority.
For H-PPPs, expenditure categories of the reformed CPC would cross-classify some of the most relevant ICHA-HC and ICHA-HP classification principles but not all.

5. Consolidating and expanding the variable list of the Eurostat-OECD PPP project

Choosing the measurement unit: input versus output and outcomes

There is now an emerging consensus about the meaning and use of these concepts in price comparisons, and although the terms of input, output and outcome are not well defined in SNA93, “the theory of non-market prices” seems now in reach (Lequiller, 2006). At the core of this consensus is that “output methods” are recommended for compiling indicators of volume change of non-market services, at least for the case of national comparisons over time.

This chapter will briefly review this emerging consensus. It describes how such a method based on price-(cost) weighted averages of quantity indicators can be applied for H-PPPs. The question about the need for quality adjustment and alternative strategies to do so will be dealt with separately in the chapter on quality adjustments.

Comments and proposals on the list of health items in the Eurostat-OECD PPP project

There seems to be a general agreement that the current variable list for the health care headings in the questionnaire of the OECD-Eurostat PPP project is unbalanced. On the one hand, medical goods, such as pharmaceuticals are well represented. On the other hand, no output or product price data are collected for the large spending item of public expenditure on inpatient care in hospitals, for which only input prices are collected. Moreover, private expenditure in hospitals is not covered with own indicators. There is also room for improvement of the indicators on long-term care expenditure, e.g. by data on care provided in institutions.

11.06.11.0 Pharmaceutical products [COICOIP 06.1.1]

For this product group, the current planning of the next PPP round seems already to foresee the reduction of the great number of individual items covered. A main issue for international comparisons is here that countries differ substantially in the public-private mix of funding. The pharmaceutical market is heavily regulated in all countries but countries differ, for example, in the range of substances that private households can buy “over-the-counter”.

For prescription drugs, national reimbursement lists exist in many cases, and regional variations tend in these cases to be limited. There is, however, a trend in several countries towards partial deregulation of the pharmaceutical market that would lead to more price competition between pharmacies. The possible implications for the H-PPP project of “split markets” in the future between traditional pharmacies
on the one side and pharmacy chains or other supply channels on the other need to be kept in mind.

Under publicly provided health care, not every new – and often expensive – pharmaceutical innovation finds its way in the list of publicly reimbursable prescription drugs. This has let to the emergence of a (smaller) market for privately funded prescription drugs for patients who can afford these. In co-operation with specialists in pharmaceutical pricing and pharmaceutical policy, it should be decided if selected corresponding items should be introduced to the pharmaceutical section of the H-PPP project.

11.06.13.0 Therapeutic appliances and equipment [COICOP 06.1.3]

For these two sections, it is important to check if new, usually higher-priced items are sufficiently covered. For higher-priced items, such as hearing aids or glasses of higher quality (where aesthetic aspects play an important role), the boundary between public and private reimbursement has started to shift. In these cases, the public reimbursement rates often cover substantially less than half of the actual or “typical” price that most private consumers are willing to pay. Rules have then to be discussed for how to allocate the corresponding spending, and how to find adequate weighs for aggregation in these cases. This should be addressed in a pre-test of any refined specifications that health care specialists should conduct in a number of countries.

11.06.21.0 Medical Services [COICOP 06.2.1]

For this section, more specific case vignettes are proposed in addition to the existing ones. These refer to specific health problems and allow a more precise mapping to national data systems. For that purpose, a number of more complex outpatient (and day-patient) services should be included in the list and specified in detail, such as a paediatric consultation, cataract surgery or colonoscopy (all three examples are from the HealthBASKET project: see annex 1). For selection criteria for increasing this list, and criteria on the overall scope of an amended list, see the section under “11.06.31.0 “Hospital series”.

An important challenge of this (and the next section) is the calculation of price indicators that reflect the typical “full price” of services, including private cost-sharing. Cost-sharing arrangements have become more and more complex in many countries with many exceptions granted on medical or social grounds. In some cases (e.g. Germany), cost sharing is a fixed amount per first treatment during a given time period (e.g. 10 Euro in 2006 per each quarter in which any GP consultation takes place), but then independent of the number of visits. The average private cost-component of individual services (here one consultation with a GP) can therefore be difficult to obtain, and consequently the total price that adds up the public and private component, as well.

In addition there are usually a number of exemptions, e.g. for younger persons, or for certain types of consultations (e.g. consultations for prevention without treatment needs, in Germany). This example already points to a common strategy to get around a number of comparison problems, which is the definition of more specific cases, or case-vignettes than “general consultations” and the like. These detailed specifications
should include a number of parameters, such as age of patient, disease severity, first-contact etc. that would help to measure the corresponding price/output more precisely. To take the above example, for a first-contact visit one would assume that the full cost-sharing applies for persons older than 18.

*Example: Paediatric consultation: cough*

This is an example of a more specific – and frequent – consultation, the inclusion of which could enhance the precision of comparisons of prices/volumes of physician consultations.

---

**Case vignette: Cough**

Parents presenting at a GP/ paediatric GP office with their 2 or 3 year old child having cough and fever (38.5°C) since two days. Treatment will include drug prescriptions and a second visit may be scheduled for many patients.

*Source: HealthBASKET project*

It seems important to include one or several case vignettes for complex day-cases, as more and more health spending is shifted to this sector, away from traditional hospital care. Cataract surgery and colonoscopy are standard, and fairly well documented examples.

*Day-case surgery: cataract*

---

**Case vignette: Cataract operation**

Male, 70-75 years old, has consulted a hospital clinic/ ophtalmologist’s office because of blurred vision. After clinical assessment a diagnosis of Cataracta Senilis is made and the patient put on the operating list. The case vignette concerns the actual operation in the hospital/ ophtalmologist’s office (depending on country, please state) including any pre-operative assessment (possibly in separate visits). The procedure is performed on a day-surgery or out-patient basis.

*Source: HealthBASKET project*

Separate sub-cases may result depending on the type of implant/ ocular lens used, for which costs can differ substantially.

Mapping to ISHMT: H25-H26, H28 (ICD-10 coding) (if provided in a hospital setting).
Complex diagnostic procedure (on a day basis): colonoscopy

Day-cases also increasingly include complex diagnostic procedures, such as colonoscopy.

Case vignette: colonoscopy

Male 60-70 year old with positive Faecal Occult Blood test is referred to an internist’s/ gastroenterologist’s office/ hospital out-patient department for diagnostic colonoscopy. Start of vignette: patient presents for the first time in office/ out-patient department. The case should ideally include all visits including the one where the colonoscopy is performed (i.e. most likely two). Cases with polypectomy during colonoscopy, pathological examinations and follow-up visits are excluded.

Source: HealthBASKET project

Sub-cases of different quality may be specified depending on which sedatives, e.g. Benzodiazepines (flumazenil), or fluids etc. are used/ prescribed and these might be used for accounting for quality differences.

11.06.22.0 Dental services [COICOP 06.2.2]

For this section, the list of items should be checked to make sure these are indeed the most frequently, “typical” procedures. This raises, for example, the question if tooth extraction with multiple roots are more frequent than the currently included item (one root). There may also be the case for moving some items closer to the “whole treatment” status, such as by including anaesthesia. It is important to include different variants of tooth fillings, as these represent different quality levels. Countries are currently at different stages of replacing Amalgam filling with composite fillings, although there are pros and cons for both (concerns over allergic reactions versus mechanical stability).

11.06.23.0 Paramedical services [COICOP 06.2.3]

For these services, it is save to assume that national accounting practice differs substantially in the way boundaries between “health” and other social services are drawn nationally. The current list of items includes services, the expenditure on which will typically not be classified under “health” but under other social spending. The current list of items would indeed better fit the standardised definition of the health boundary in SHA-based health accounts. For one item, the item on childcare, it is dubious if this should be considered a health item. It may be omitted in the future.

More (disease-)specific definitions of some items should be considered, such as for physiotherapy. A model for this could be the following (taken from the HealthBASKET project, but which will need to be translated in the standard presentation of items in the PPP project).
Case vignette: Ambulatory physiotherapy (knee)

Male 25-35 years after anterior cruciate ligament reconstruction, consulting for
ambulatory rehabilitation after discharge from hospital (with a referral if necessary in
the country). Repair and hospital stay were without complications and discharge
occurred after average length of stay. Unit of measurement should be single session of
physiotherapy typically performed for this type of patient (other than in the
HealthBASKET project).

Source: adapted from HealthBASKET project

11.06.31.0 Hospital services [COICOP 06.3.0]

It is important to develop a set of case vignettes\(^3\) for comparison of hospital
(inpatient) production. For hospital care, this includes both elective and emergency
cases. This is the subject of the next chapter.

---

\(^3\) A case vignette describes a typical case or episode of care by specifying, among others: age (and gender),
circumstance of contact with the health care system (e.g. presentation as emergency case), case history (or its
absence), standard treatment and type of discharge, absence of complications etc.
6. A proposal for an improved questionnaire on hospital services

This chapter proposes a short list of twenty hospital case vignettes that extends the list of eight inpatient case vignettes that are currently being tested under the major, “HealthBASKET” project that is funded under the European 6th framework programme of research. Accordingly, this chapter again recommends starting with a core list that is currently extensively tested under the HealthBASKET project.

The proposed short-list has a focus on vignettes that clearly distinguish between acute inpatient episodes versus corresponding post-acute, rehabilitative and ambulatory care events, because a fully disease-based approach is currently too complex to be feasible for a larger number of countries and vignettes. Before presenting a proposal for a list of vignettes, a number of design criteria of a questionnaire on hospital services for improved H-PPPs is discussed. It next presents a short list that covers a selection of most frequent procedures, some of them accounting for a considerable share of total inpatient expenditure, such as normal delivery, stroke, and AMI.

Box 3. Differences between the H-PPP project and the ARD project

There are important differences between the project of a questionnaire on inpatient services for the purpose of collecting information for the construction of H-PPPs that is outlined in this chapter and the OECD ARD project. The H-PPP project has a focus on cost and volume information only. It does not make an attempt to analyse characteristics of the health system design that explain differences in treatment patterns, or to measure outcomes. Moreover, the inpatient component of a refined H-PPP project should more systematically exploit links to existing and emerging data standards, such as the latest ICD classifications, and the improvements in OECD Health Data that have happened since the OECD ARD project was started. As has been recommended by Tripplet in his comments on the results of the ARD project and its potential for constructing improved H-PPP, the measurement of both unit-cost or price information and of volume information should be considered (Tripplet, 2003:139).

How many items should the list of hospital cases include?

For the decision on the overall number of procedures to be included, the following criteria have to be considered:

(1) The more items are included, the less resources are available that can be spent per item for a given budget for the international comparison. The complexity of any international comparison of health data on procedure level suggests that the number of items has to be kept short. This is also supported by the experience of the OECD ARD project with respect to data problems and comparability.

---

4 First results on cost-estimates and from analysis of the comparability and reliability of data based on these case vignettes have become available in September 2006 with final country reports and a draft synthesis due towards the end of 2006/early 2007.

5 The OECD Ageing-Related Diseases (ARD) study provided information on the cost of specific treatments for heart disease, stroke and breast cancer (OECD, 2003). All three disease groups are included in the proposed short list.
There is, however, evidence that the variability of prices and quantities across services can be large in international comparisons, which means that only averages over a larger number (sample) of procedures will lead to representative comparisons.

As a result, the number of items should be clearly longer than the list analysed in the HealthBASKET project (which looks at eight inpatient cases), but certainly much smaller than, for example, the list of around 150 items of the new International Shortlist for Hospital Morbidity Tabulation (ISHMT), which is designed to compare hospital discharge statistics according to ICD-10, a classification which does not provide a classification by case vignettes, because very different treatments will in many cases belong to the same disease heading (Box 4 below).

The current proposal in this chapter comprises 20 case vignettes, which is a compromise between the criteria (1) and (2) listed above. Implementation of this list will, however, already be resource demanding, as the amount of work to designing and comparing a single case vignette in a meaningful way are considerable – a key message from the HealthBASKET project.

**Which items should be included?**

The list of items to be included should cover the major disease areas and the most common health problems. These should either be among the most frequent cases for hospitalisation or among the most important for health policy of ageing populations in OECD countries: therefore the inclusion of the hip and knee-replacement procedures.

Indicators should also allow for mapping to the *International Shortlist for Hospital Morbidity Tabulation* (ISHMT) originally developed by the European Hospital Data project (see Box 4). The ISHMT is a new international standard for collecting inpatient case statistics by international organisations and will - together with the draft WHO *International Classification of Procedures in Medicine* - be a major driving force for improving future international data collection in this area.

It should, however, be noted that the ISHMT indicators themselves will in most cases not be detailed enough to represent individual cases of sufficient homogeneity for international comparisons, because disease categories of discharges do not specify, which procedures or kind of treatments have been performed, - information that is essential for correct costing or selection of price information.

Case vignettes should clearly have a focus on items for which there is already sound experience with international data collection. The proposed list has therefore a good overlap with volume indicators collected in *OECD Health Data* under the “Surgical procedure” chapter. But here again, it remains to finally be decided during a pilot phase to which extend more narrow cases need to be defined, such as by restricting the age bracket and by having a focus on cases without complications and with only limited co-morbidity in order to improve comparability across countries (see also the remarks below on the appropriate level of detail of case vignettes).
Box 4. International Shortlist for Hospital Morbidity Tabulation (ISHMT)

The Hospital Data Project (HDP) of the European Union Health Monitoring Programme has compiled a shortlist for statistical comparison of hospital activity analysis, adopted in 2005 by Eurostat, the OECD (Organisation for Economic Co-operation and Development) and the WHO-FIC (Family of International Classifications) Network.

Comparison of hospital activity

The special tabulation list for morbidity published in ICD-10 volume 1 consists of 298 groups defined by their ICD-10 codes. For international comparisons of hospital morbidity statistics this list has been regarded too extensive. The ISHMT short-list comprises around 150 items.

Applicable with different versions of ICD

Furthermore, the simultaneous use of ICD-9 and ICD-10 has called for a shortlist consisting of groups defined by both ICD-9 and ICD-10 codes for comparisons between countries using different ICD revisions and for developing time series statistics.

An international agreed standard

The Hospital Data Project (HDP) of the European Union Health Monitoring Programme aimed at maximising the statistical comparability of hospital activity analysis. The proposed shortlist was later discussed with major providers of international hospital statistics such as Eurostat and OECD. After a few minor modifications it was adopted in 2005 by Eurostat, OECD and NOMESCO for data collection and presentation. At the WHO-FIC Network Meeting in October 2005 the list was also adopted by the WHO-FIC Network. It has now been published on the WHO website as the International Shortlist for Hospital Morbidity Tabulation (ISHMT) (Version 24-11-2006).

Source: adapted from WHO (2006)

See also: Magee, 2003 and Magee et al, 2003, .

How detailed should case-descriptions be?

A crucial decision is how specific case-descriptions should be. These decisions have in particular been made with the main data systems in mind that are available in countries. Data coded according to national DRG systems are a typical candidate in this respect.

For broader descriptions, several DRG-specific cases will often be available in national data systems, which will need to be averaged or from which a selection has to be made. If categories (cases) are defined too narrowly, no national DRG group might exist that exactly fits to the international definition.
The more detail, on the other hand, a case-vignette description offers, the less comparability problems arise from different case-mix (severity) or treatment mix between countries. It is one of the main lessons from the HealthBASKET project and of other previous international comparisons that case-vignettes have to be rather specific and detailed in order to lead to comparable data (see also the analysis in the next chapter on how to define a number of case vignette variants to account for differences in quality).

The original HealthBASKET case vignettes have usually been retained in the proposal of this chapter. The available final country reports on this project suggest, however, that some of the vignettes might be too small to allow mapping of national data, whereas others were probably too large, bringing together different technologies between countries, for which examples are provided in this chapter. The twenty case vignettes proposed here correspond to the broader categories in this respect.

The last point raises the question of whether a two-step approach would be feasible: the identification of, first, a (limited) number of broader defined cases, under which “varieties” will be defined that refer to well-defined differences in treatment, mainly defined by health technology and drugs used. Such a two-step approach might allow for capturing quality differences between countries by calculating appropriate case-mix indices. It is recommended that such an approach is testing with a pilot questionnaire for price comparisons of hospital cases.

Any revision and further design of the cases proposed below should take into account the lessons from the final synthesis report of the HealthBASKET project that will become available in the first quarter of 2007.

**A proposed shortlist**

The following Table 4 provides an overview on the proposed case vignettes that are described in more detail below. This table shows which of the proposed case-vignettes have been studied in depth by the HealthBASKET project. Furthermore, a mapping is provided to ICD-10 disease codes, both for a more narrow and for a wider definition of case vignettes. This mapping to ICD-10 is important for linking to national DRG systems (see also the sections below about DRG systems).

For each item, the corresponding ISHMT category is provided to which the case belongs. As Table 4 shows, a single ICD-10 code corresponds to a number of cases in question (such as for hip and knee replacement). For other items, the corresponding “proxy” ISHMT category is substantially broader than the proposed case-vignette. The last column indicates whether a corresponding (surgical) procedure is included in the list of indicators of OECD Health Data under the “Surgical procedures” sub-chapter on health care utilisation. This is the case for a third of all 20 proposed case vignettes.
Table 4. A proposed shortlist of inpatient case vignettes

<table>
<thead>
<tr>
<th>Case vignette</th>
<th>HealthBasket Vignette</th>
<th>ICD-10 Code</th>
<th>ISHMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>---</td>
<td>narrow</td>
<td>wide</td>
<td></td>
</tr>
<tr>
<td>1 Malignant neoplasm of bronchus and lung</td>
<td>---</td>
<td>C34</td>
<td>C34</td>
</tr>
<tr>
<td>2 Malignant neoplasm of breast</td>
<td>---</td>
<td>C50</td>
<td>C50</td>
</tr>
<tr>
<td>3 Mental and behaviour disorders due to alcohol</td>
<td>---</td>
<td>F10</td>
<td>F10</td>
</tr>
<tr>
<td>4 Cataract senilis</td>
<td>Vignette 4</td>
<td>H25.0</td>
<td>H25-H26</td>
</tr>
<tr>
<td>5 Angina pectoris</td>
<td>---</td>
<td>I20</td>
<td>I20</td>
</tr>
<tr>
<td>6 AMI</td>
<td>Vignette 6</td>
<td>I21</td>
<td>I21-I22</td>
</tr>
<tr>
<td>7 Heart failure</td>
<td>---</td>
<td>I50.0</td>
<td>I50</td>
</tr>
<tr>
<td>8 Stroke</td>
<td>Vignette 5</td>
<td>I60-I63 (or I63)</td>
<td>I60-I67</td>
</tr>
<tr>
<td>9 Varicose veins of lower extremities</td>
<td>---</td>
<td>I83.9</td>
<td>I83</td>
</tr>
<tr>
<td>10 Pneumonia</td>
<td>---</td>
<td>J18.0</td>
<td>J18</td>
</tr>
<tr>
<td>11 Appendectomy</td>
<td>Vignette 1</td>
<td>K35.1</td>
<td>K35-K38</td>
</tr>
<tr>
<td>12 Hernia inguinalis</td>
<td>---</td>
<td>K40</td>
<td>K40</td>
</tr>
<tr>
<td>13 Choleliatis</td>
<td>---</td>
<td>K80</td>
<td>K80</td>
</tr>
<tr>
<td>14 Hip replacement</td>
<td>Vignette 3</td>
<td>M16.0</td>
<td>M16</td>
</tr>
<tr>
<td>15 Knee replacement</td>
<td>---</td>
<td>M17.0</td>
<td>M.17</td>
</tr>
<tr>
<td>18 Normal delivery</td>
<td>Vignette 2</td>
<td>O80</td>
<td>O80</td>
</tr>
<tr>
<td>19 Fracture of femure</td>
<td>---</td>
<td>S72.0 (or 72.2)</td>
<td>S72</td>
</tr>
<tr>
<td>20 Fracture of lower leg, including ankle</td>
<td>---</td>
<td>S82</td>
<td>S82</td>
</tr>
</tbody>
</table>

Source: own compilation

Description of case vignettes

**Malignant neoplasm of bronchus and lung**

For the definition of this case vignette, a further narrowing down for the condition and procedures provided is needed, as the corresponding ICD-10 code can stay for a wide range of treatment choices. The comparability of the existing ISHMT data as volume indicators may be is limited by differences in the case mix between countries, and this needs to be further analysed during a pilot phase.

**Malignant neoplasm of breast**

Here a precise case vignette needs to be defined. *OECD Health Data* collects to indicators for related surgery: total mastectomy (US ICD-9-CM, 85.4) and “breast conserving surgery” (US ICD-9-CM, 85.2). The changing case-mix might correlate
with improved quality of care (the second volume indicator varies more between countries), but it will be difficult to do the corresponding adjustment for severity of cases in order to quantify this for international price-volume comparisons.

**Mental and behaviour disorders due to alcohol**

This is one of the most frequent primary discharge diagnoses for hospital inpatient cases. Due to the challenges of defining a comparable case vignette for this diagnosis, this case may remain experimental for a while before it will be included in price comparisons on a routine basis. According to *OECD Health Data*, length of stay for this condition varies greatly in OECD countries, ranging in 2004 from 3.5 (Sweden) to 29.7 (New Zealand), which may point, among others, to differences in the division of labour between institutional and community services, and these need to be analysed for the definition of a good case vignette.

**Cataract senilis**

The same case vignette that was proposed for day-services would also apply here (see Chapter 5, above). *OECD Health Data* collects data on cataract surgery and uses US ICD-9-CM as a reference (13.1 – 13.7). It would be preferable to use for more precise measurement for H-PPPs the restriction to senile cataract, which is by far the most common procedure performed.

There is evidence from the HealthBASKET project that differences in prices are to a large extent due to differences in the price of the lens implant (see, *e.g.*, Tan et al., 2006).

**Acute Myocardial Infarction (PTCA)**

Case vignette: Acute Myocardial Infarction (PTCA)

Up to the moment of presentation healthy male, 50-60 yr. old, who has developed a sudden acute chest pain. An ambulance is called and transports the patient within 2 hours of the onset of symptoms to the hospital (accident & emergency department, cardiology or ICU depending on country/ hospital). The patient shows typical ECG alterations and is admitted and treated for AMI. The patient is diagnosed and treated according to normal hospital standards (if a PTCA is performed, there are no complications, i.e. a referral to cardio-surgery is excluded); progress is average for age. End of vignette: discharge to rehabilitative institution or home.

*Source: HealthBASKET project*

There will be a number of variants, such as on number and type of stents and it is important to distinguish these (Mason and Smith, 2006, for England). (See also the remarks below under the quality section.) This case vignette will need refinement, once the synthesis report of the HealthBASKET project has become available. During the pilot phase, an addition synthesis for the recent literature on the international comparisons of health disease treatment should be included that could potentially be relevant for an improved case-vignette.
Stroke

Case vignette: stroke

So far healthy female (i.e. no co-morbidity), 60-70 years old, with sudden severe hemiparesis (right side) and dependency, with severe aphasia. Admission to hospital (accident & emergency, medical or neurological department depending on country/hospital) by ambulance car. Start of case vignette: hospital door. All the interventions including diagnostic and treatment are delivered in the same hospital. The patient is diagnosed and treated according to normal hospital standards (which may or may not include a stroke unit, early rehabilitation etc.); progress is average for age. Transient (TIA), short and reversible (RIND) and prolonged and reversible (PRIND) ischaemic neurological deficits are excluded. End of vignette: discharge to rehabilitative institution or home.

Source: HealthBASKET project

Results from the HealthBASKET project suggest that differences in average length of stay account for an important share of price (cost) differences (e.g. Mason and Smith, 2006). There are also cost-relevant differences in the rate of CT scans versus more costly MRI scans that are performed for diagnosis (e.g. Schreyögg et al., 2006, for Germany).

Varicose veins of lower extremities

This procedure is currently included in OECD Health Data in the chapter on “surgical procedures”. OECD Health Data uses US ICD-9-CM as a reference (38,5), which in principle should provide a sufficiently detailed case vignette. Emerging international standards should also be consulted for this purpose, such as the draft WHO International Classification of Procedures in Medicine. The corresponding ICD-10 code is one of the most frequent discharge diagnosis across countries.

Appendectomy

Case vignette: appendectomy

Otherwise healthy male, ca. 15 to 20 years old, presents to hospital (accident and emergency department if existing; otherwise directly to surgical department) with acute abdominal pain. Start of case vignette: hospital door. Abdominal palpation yields typical signs of appendicitis. End of vignette: discharge.

Source: HealthBASKET project

OECD Health Data 2006 reports here the total numbers of inpatient procedures but with no detail of case severity or age. Data availability is fair with 23 countries currently reporting.
Results from the HealthBASKET project suggest that average length of stay is an important factor for determining differences in cost and prices. There are also price differences between laparoscopic surgery and traditional surgery, with laparoscopic surgery perhaps more cost-efficient (e.g. Tan et al., 2006, for the Netherlands; and Bellanger et al., 2006, for France). The share of cases that have received a CT abdomen (recommended as good practice) also plays a role.

*Hip replacement*

**Case vignette: hip replacement**

Female, 65-75 years old, with hip osteoarthritis requiring hip replacement because of considerable impairment is finally (after waiting time if normal in the hospital) admitted for her first hip replacement (one side). The patient is without co-morbidity (i.e. expensive drugs due to treating co-morbidity should be excluded), the surgeon uses the most frequently used implant for female patients; the operation is without severe complications; end of case vignette: discharge (to the home or to separate rehabilitation institution). The surgical procedure is provided in an acute hospital setting without the extended rehabilitation that may follow surgery.

*Source: HealthBASKET project*

OECD Health Data 2006 reports the total numbers of inpatient procedures but with no detail of case severity or age bracket. Data availability is fair with 23 countries reporting currently. Waiting times are an important quality consideration for this case vignettes.

The HealthBASKET project has shown that differences in the material costs for hip implants are the most important predictor for differences in unit cost (e.g., Schreyögg et al., 2006, for Germany).

*Knee replacement*

**Case vignette: knee replacement**

Female, 65-75 with knee osteoarthritis requiring knee replacement because of considerable impairment. First knee replacement (one side), using the most frequently used implant for female patients, aged between 65 and 75, without co-morbidity, and severe complications. The surgical procedure is provided in an acute hospital setting without the extended rehabilitation that may follow surgery.

*Source: adapted from case vignette 14, above.*

OECD Health Data 2006 reports the total numbers of inpatient procedures but with no detail of case severity or age bracket. Data availability is fair with 20 countries reporting currently. As with hip replacement, waiting times are an important quality consideration for this case vignettes.
**Renal failure: dialysis**

OECD Health Data currently collects the total number of patients undergoing dialysis and there are about 20 countries that report data on this item. For the international comparison of prices and volumes, it would be desirable to collect estimates of the mid-term costs of dialysis patients over several months. It will be further analysed and decided which sub-cases should be defined from the list provided in the OECD definition, and whether these sub-cases differ systematically in cost/prices and quality, for example if the most common form of dialysis at an institution is compared with dialysis at home.

**Definition: Patients undergoing dialysis**

The number of patients with dialysis treatments includes Hospital/Centre and Home Haemodialysis/Haemoinfiltiration, Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis (CAPD), and Continuous Cyclical Peritoneal Dialysis (CCPD) on December 31st of each year.

*Source: OECD Health Data 2006*

**Renal failure: transplant**

OECD Health Data currently collects the total number of procedures conducted during the year. Data availability is generally good with all 30 countries reporting data for the year 2003. For design of detailed case vignette, allotransplants may have to be distinguished from other transplants. For this category, a range of prices from under 10,000 Euro (Netherlands, Poland) to over 50,000 (Germany) have been reported (ScHARR, 2002:52), which means that probably both measurement problems and real differences in prices are large.

Note: There are additional variables in OECD Health Data that can potentially be used for checking the quality of data that will become available for this and the former case vignette: total number of end-stage renal failure patients and

**Normal delivery**

**Case vignette: normal delivery**

Healthy woman, 18-25 years old, presents to hospital after 39 weeks of an uncomplicated first pregnancy with labour pains. Start of case vignette: hospital door. Upon examination of the woman, the (single) baby presentation is normal (i.e. cephalic/ vertex; one foetus) and a vaginal “normal” delivery is carried out without complications. End of vignette: discharge of mother and child.

*Source: HealthBASKET project*
Normal delivery is an item in the new ISHMT shortlist for inpatient discharge statistics, which is now commonly used by OECD, Eurostat and WHO-Europe as “single spontaneous delivery”. Data availability in these data collections is generally good for this item. However, there seem to remain serious comparability problems between countries in the definition of this item and in its delimitation versus other discharge categories of birth.

This is illustrated by the weak correlation between the total numbers of births in a given year with inpatient discharges recorded under this item. Difference in the coverage of reporting (all or only a selection of inpatient institutions) might also play a role (Figure 1).

Moreover, countries differ with respect to the share of births at home. As the HealthBASKET project has noted, this share can influence cost and prices for births at hospital. Births at home are usually selected among the births that are expected to be without risk of complication, which leaves a different case-mix for hospitals. This has to be kept in mind, for example, when a country such as the Netherlands, where around one third of all births are births at home, is compared with other counties (Tan et al. 2006).

Figure 1. Weak correlation between birth rates and discharge statistics raises a number of questions

Caesarean section is a potential candidate to be added as case vignette to the list proposed in this chapter, in order to broaden the coverage of childbirth in the H-PPP exercise. This item is reported in OECD Health Data (number of cases), but not included in the ISHMT short-list for discharge statistics as individual item.
A note on the sampling design

The OECD-Eurostat PPP exercise usually limits the survey of prices to the area of a country’s capital in order to contain the costs of this project. For health care, and for other social services, such as long-term care, however, it is important, to keep in mind that prices of services provided in the capital can be substantially higher than in other areas of the country. This would not be a problem, if the relative difference between the capita and the rest of the country were roughly the same for all countries. But there is no reason to believe that this would be the case.

More generally, the regional variability of unit costs and prices in health care tends to be large and the balance of evidence suggests that these variations are in many cases not correlated to specific characteristics, such as quality of services (see, e.g., the overview by Porter and Teisberg, 2006:46ff for the US). Salaries, which are a main cost component, may be higher in some regions with higher average per capita income. In addition, University and other teaching hospitals that are concentrated in the capital may perform functions of research and education that allow them to charge higher prices or to charge higher reimbursements per units of services (Box 5; see also the comments below on the design of DRG systems).
Box 5. Examples of regional variations in unit costs of medical care

The cost per Medicare enrollee in the US

Exact information on regional variations in unit cost or prices are difficult to obtain, but proxy information on regional variations exist and these are often too large to explain them by differences in case-mix or case-load. For the USA, e.g., there is an almost threefold regional variation in annual cost per Medicare enrollee, with expenditures ranging from less than $3,000 per patient in some areas to more than $8,500 in others (Porter and Teisberg, 2006:47).

The cost of colon cancer in Ile de France

A recent study in France has analysed the per capita expenditure on colon cancer in Paris and neighbouring cities for the year 2002. This has been controlled for severity level of the initial diagnosis, and type of treatments provided. Expenditure was calculated for whole treatment, of which hospitalisation accounted for the bulk of care (around 85%). This study allowed calculating case-mix adjusted differences in spending per patient, which were of the magnitude of 15% to one third between Paris and neighbouring regions (for Departments and for the “Grand couronne”, respectively). For the total sample of all departments, the maximum reported difference was 46% between Paris and les Yvelines (Com-Ruelle, et al., 2005).

The cost per home care client in long-term care in Scotland

There is huge variation in annual expenditure per home care client across local authorities in Scotland (Bell and Bowes, 2006), ranging from around £1,500 to almost £8000. These can only partially be explained by differences in the way long-term care is provided (community care versus care in institutions), client characteristics (unfavourable demography on some islands) and differences in efficiency (the relative low costs for West-Lothia are partially due to the success of innovative integrated care delivery).

The role of DRG systems in mapping (hospital) inpatient services

For countries with DRG systems (and this is now the vast majority), there will usually exist one or several DRG groups that correspond to each of the twenty case vignettes proposed in this chapter for refined H-PPPs. It needs then to be decided on a case-by-case basis, which national group should be mapped to the corresponding item and this will need to be determined during a pre-test of the new item list, with the involvement of experts in health statistics in member countries. Once these individual links have been established on national basis, they need to be revised whenever relevant changes occur in the DRG groupings used.

DRG systems in OECD countries have common routes and share certain basic classification principles, such as references to the International Classification of Disease (ICD). DRG systems have, however, in most cases undergone major modifications before they were adopted in individual countries (see Figure 2).
The primary aim of the European Commission funded project HealthBASKET (2004-2007, DG Research, 6th framework programme) is to develop a methodology which allows comparisons of the costs of individual health services between different EU Member States. Moreover, this project explores the reasons underlying the variations in costs of individual services between countries. “Cost” is the preferred term in this project over “prices”, a term that is reserved for situations where a (quasi-) market of service providers exists (see Annex 1). However, this project also analysed in detail the extent to which DRG systems (reimbursement items) reflect actual costs for the procedures and treatments in question, and about the use of DRG mappings to generic case-vignettes for international comparions.

The interim conclusions from the European Commission funded project HealthBASKET state that differences between European DRG systems are substantial and that these systems are “incomprehensible and incompatible” (Schreyögg, 2006) if data would be taken from them as such, ie. without further standardisation and mapping to more generic case-vignettes of the type proposed in this chapter.

While DRGs have spread across Europe, DRG systems have diverged and followed different paths over the past two decades, following complex paths of adjustments (Figure 3). Along these paths, their development was heavily influenced by different preferences in medical practice and new technologies” between countries. Moreover, DRG systems tend to undergo frequent revisions, to take into account medical technical progress and the need to update the costing process more generally.
For this reason, national DRG systems can only be the starting point for international comparisons. A number of transformations will be needed based on each individual system. These include:

- Selection of samples of DRG codes to be mapped for each case-vignette;
- Strategies to account for differences in case severities of individual DRG codes compared with the (international) case vignette;
- Design of weighting schemes for these (e.g. based on cost weights);
- Alternative weighting for each individual case that includes both cost and quality information (described by differences in medical technology and outcome, where this information is available);
- Determination of “mark-ups” needed to transform DRG reimbursements to “full cost” values, such as by adding depreciation for (fixed) capital utilisation and separation of “service fee” component for special role of hospitals as teaching hospital or research centre and the like.

Figure 3. Typical paths in establishing DRG systems

![Diagram showing the typical paths in establishing DRG systems]

Source: J. Schreyögg et al. (2006)
7. Accounting for differences in the quality of services

There is now an emerging consensus in principle that comparisons in health care – both between countries and over time – have to account for differences/changes in the quality of services. There is less agreement on how to measure quality.

Systematic and comprehensive measurement of quality in health care at the aggregate level is still in its infancy in all countries and there are large gaps in the knowledge about what determines differences in quality where these are apparent. This is not only an issue for comparisons at aggregate level between countries, but an observation that has been made on all levels of health care provision, from the individual provider to regions, and countries. The weak correlations that has been observed at all levels (scales) of health care provisions between resource utilisation and unit-costs and output or outcome, indicate that many providers and therefore health care systems at the aggregate level do not operate at what could be thought of conceptually as “production frontiers” for quality-adjusted output.

This has a number of reasons. Productivity gains, for example, that would be possibly using new technology may not be applied systematically. Moreover, old and new technologies (different vintages) often co-exist for longer time than would be suggested if providers explored efficiency gains in fully systematically ways.

University hospitals or other providers of health care that operate with higher unit prices across the board, frequently excel on some procedures but can have average of below-average results for others. These variations in medical care practice have been found at all levels of health care systems (within large provider institutions, between providers of a certain region), but also between countries that are the unit of observation for H-PPPs.

First results from the OECD Health Care Quality Indicator project seem to confirm these findings on the aggregate level (Kelly and Hurst, 2006). Countries that perform better than others on one or several indicators do not necessarily perform better on other indicators. Not surprisingly, correlation of indicators for procedures on conditions that are closely related, such as different types of stroke are closer correlated than indicators for procedures that are more remote, such as cerebrovascular treatment versus cancer treatment (Figure 4 and Figure 5).
Figure 4. Countries do not perform consistently better on several quality indicators

As Figure 5 shows, countries with similar AMI fatality rates can differ widely in stroke mortality.

Figure 5. Correlation of quality dimensions is often week

Although there is some evidence that expenditure and therefore most likely unit-costs are statistically significantly correlated with a number of the indicator from this
new data set, when compared across countries, it remains to be seen if these correlations are strong enough to allow for quality adjustment once price/unit cost information for individual services have been identified.

**Choosing homogeneous groups of services with distinct difference in quality**

When services can be sufficiently differentiated in the H-PPP questionnaire, individual case vignettes may be broken down into separate categories that should be linked as close as possible to internationally established clusters of medical practice, for which there is sufficient medical knowledge to distinguish quality differences between them. When new technology replaces old ones (e.g. the use of uncemented versus cemented implants for hip-replacement), there is usually a period where both technologies are used in a given country. The following gives examples of quality aspects for services in different product groups (other than those already mentioned under the individual vignettes).

**Dental care**

For the case vignettes on dental care there are different sub-types that correspond to differences in quality and these should be captured in a draft questionnaire for empirical testing. First there is the question if the procedure is performed under anaesthesia. Second, there are differences in the material used for filling. Finally, for amalgam fillings, the polishing after filling, which is critical for the durability of the filling, usually needs a second visit (with the need for aggregating these to one “treatment episode”, whereas this procedure is usually performed in one visit or more modern fillings.

**Hip replacement**

For hip replacement, procedures that use uncemented implants are substantially more expensive. They have become the rule in some countries but not in others.

**Acute myocardial infarction**

There is an ongoing medical discussion about effectiveness and quality of care of different procedures frequently performed in this case. Perhaps most prominently illustrated at the moment by new research that has questioned that expensive drug elusive stents provide any advantage in terms of outcomes and survival rates. Results from the HealthBASKET project have shown that using high- versus low-cost stents, and the number of stents, explains much of existing price differences in countries (e.g., Mason and Smith, 2006, for England; and Bellanger et al., 2006, for France).

**Quality adjustment with measures of health gains?**

The idea that quality differences should be measured by accounting for differences in services to the contribution to outcome has increasingly been recommended by some and some possibilities would in fact exist to account for difference in the marginal benefit for the consumer that result of differences in the quality of the services. Perhaps most prominently, this has been one of the recommendations from the Atkinson report for strategies to improve price and productivity measurement in the UK (see Box 6 below).
Box 6. Atkinson recommendation: Principle B (see para 4.24)

“An output measure should be adjusted for the attributable incremental contribution of the activity to individual or collective welfare. This should include capturing any change in outcomes which is attributable to the use of the inputs. A basic count of activities does not measure the quality of the output such as change in quality of patient experience or clinical effectiveness. This is a continued weakness of the current method and is discussed further in paragraphs 8.46-8.66.”

Source: Atkinson report, 2005

Many researchers have proposed one-dimensional summary measures of health gains (such as measured by QUALYs gained). These are usually technically very demanding, in particular with respect to the design of weighting schemes that are needed to map multiple dimensions of health status (Health related quality of life measures) into a one-dimensional measure.

Although measures like QUALYs may work well with assessing quality gains of well-defined treatments of certain conditions, their health policy implications need to be further assessed before their use for "measurement" in international comparisons could be recommended as a general rule. In the end, a pre-condition for their use is that the contribution to health gains has been well established, which for large parts of health care services is currently not the case. Moreover, new research in the efficiency and effectiveness of health care services often correct, if not contradict a substantial share of previous studies and findings.

For health services, the picture is also complicated by the fact that the patient him- or herself is an important co-producer for the outcomes of treatment (such as health gains). The placebo effect illustrates this very well. For assessing the relative utilities of various health care services to purchasers, it is important to take benefits from the placebo-effect into account, in particular as this may be the main – if not sole - (positive) outcome of many encounters with the health care system, in particular for primary care, taking into account that modern medicine has yet no convincing response to many common health problems, such as common cold or lower back pain.

There are at least two further fundamental problems in measuring marginal benefits:

1. For a large share of health interventions that target specific patient groups, few is know about the effectiveness of care including about its potential risks (appropriateness of care). Large regional variations in, e.g., rates of surgery are reported both within countries and between OECD countries that cannot be explained by differences in the prevalence/incidence of underlying conditions or health status of populations.

2. Even where there is little debate about the effectiveness of certain interventions (e.g. appendectomy for acute appendicitis) it is not clear how big the share of patients is that undergo surgery or are subject to other treatment after having received the wrong diagnoses. For these patients, marginal benefits are small or even
negative, depending on what measure of benefits is taken and what the consequences of medical error are.

A two step approach of quality measurement would therefore first inquire assessing the precision of diagnostic procedures or of screening services, and secondly enquire into the quality of correctly diagnosed patients (perhaps approximated by “cases without complications”) in administrative records?

A number of alternative choices to one-dimensional approaches could therefore be explored, starting from the framework of the OECD Quality Indicator Project and its growing network of collaborators and their ultimate choice will have to be justified based on statistical test.

Recommendations on quality adjustments for H-PPPs

From the above observations, the following box summarises the main recommendations for the role of quality adjustment in the estimation of H-PPPs.

Recommendations 3. The role of quality adjustment

For international comparisons it seems advisable to first keep (unadjusted) quantity and quality measurement separate. This would allow for more transparency. The calculation of composite indicators that adjust prices and volumes for quality differences across countries would then be an analytical step, rather than part of a process for "estimating data". The joint analysis of price, volume and quality should be kept as transparent as possible, in particular in the early phases of the project.

The main method that should be tested is the split of procedures in variants of different quality levels (as indicated by distinct differences in the medical technology used).

Independent of the choice of quality indicators for correcting volume or price data, it seems wise to test their predictive power based on econometric analysis. When quality is measured as outcome gains attributable to health care interventions it should be tested whether there is a simultaneous equation issue: higher average unit-costs or prices may result in better outcome, but the need for achieving this outcome (in the sense of greater health care need) may have led to higher average spending and prices.
8. Conclusions

There is a sequence of tasks and next steps which follow from the suggestions in this paper on improving health-specific PPPs both on disaggregate and on health sector-wide level, as well as a division of labour required.

Division of labour and resources required

As this paper has argued, the task of establishing/improving H-PPP estimates is a complex and rather resource intensive project, not unlike other attempts of improving health statistics for international comparisons, such as SHA-based health accounts and the OECD quality indicator project. A division of labour with shared burden of responsibility and sponsorship is consequently the most promising way forward. The first question is therefore how to mobilise the resources needed.

This paper has also argued that there must be synergy in co-operation between the Health Division and the Eurostat-OECD PPP project. Many of the data on pharmaceuticals and other medical goods are exactly the type of data needed for estimating solid H-PPPs. Although the Health Division could certainly help with advice on quality checking of available indicators, and work with colleagues in the Statistics Directorate on possible improvements of the list of items selected, the focus of work at the Health Division should be on complementing/improving those parts of the PPP programme, where data are very scarce, namely for market and non-market production of inpatient services.

Cooperation with interested international or European-level associations with membership in a number of OECD countries should be envisaged, such as, for example with the European Renal Association – European Dialysis and Transplant Association.

Proposal for a sequence of tasks to carry work on H-PPPs forward

In parallel to the crucial task of fund raising, which might be an important challenge, a number of tasks need to be tackled.

1. The final results from the HealthBASKET project that will become available in the first quarter of 2007 should be thoroughly analysed for their consequences for any project of improved H-PPPs. This will result in the to-date largest-scale dataset to answer the questions on how cost of services is composed and differs across countries, and how close cost comes to (administrated or regulated) prices from fee-for service lists, DRG reimbursement systems, and other tariffs. This includes the crucial questions of how much individual DRG systems contribute to actual reimbursement, versus how much is funded from other sources, such as specific mark-ups paid, or from the existence of a dual system of financing, where construction is funded separately from running costs. It also provides information about regional variation that is important for the sampling design of an H-PPP questionnaire.
2. The consequences of the HealthBASKET project for revising the shortlist of vignettes will need to be analysed. As this project has shown, it is not possible to come up with a good list of cases without some iteration. This includes the decisions on splitting vignettes in cases that correspond to different technological “vintages” and/or qualities.

3. An important iteration in this respect will next be the design of a draft questionnaire for data collection of H-PPPs that needs extensive testing with the help of an expert network from countries that need to be established, based in particular on the shortlist of twenty inpatient case vignettes proposed in Chapter 6).

4. The aggregation and measurement principles need to be also to be agreed upon: how will differing information on cost, “administrated prices”, and possible quantity information be processed?

5. In parallel to these tasks, the question of basic expenditure headings will need to be resolved: will there be a joint expenditure questionnaire to reconcile information from NA and SHA-based health accounts? Any such undertaking will need its own pre-testing and design phase, and proper resourcing.

6. A further research task will be the search for specific quality indicators for each case vignette, although actual testing of these will only be feasible at a much later stage. Perhaps only in further PPP rounds, well after 2008.

**Refinements of SHA-based health accounts and expenditure estimates**

Further harmonising the comparability of functionally defined spending items in SHA-based health accounts is an important input to the H-PPP project, providing an essential building block of data required.

Currently, SHA-based health accounts lack some of the basic breakdowns usually needed for price comparisons, in particular that in market versus non-market production. Also, a separation is needed for cost sharing from total private out-of-pocket. The later is of health policy interest in its own right as is discussed in ELSA/HEA/HA(2005)6&7.

The more difficult question is to which extent a full breakdown on the level of functions of health care into market versus non-market production is feasible and desirable. For international price/volume comparisons, various shortcuts should be considered, such as the full allocation of functions to one category by a majority of spending rule. Synergy should be the goal with national initiatives of improving health price indices linked to health accounts, because of the similar data needs that will arise from these national projects.

**The market/non-market boundary**

The distinction between market and non-market services is not a particular relevant dividing line between “comparable” and “comparative-resistant” health care services in international price-volume comparisons. Both types of output share many
of the fundamental challenges of international comparisons, such as the definition of units of measurements (activities versus output), and the problems of quality adjustment.

Moreover, the boundary line between market and non-market output has become more and more blurred over the last twenty years. A majority of publicly produced (and publicly funded) output now takes place in so-called quasi-markets for which measurement concepts of both modes of production can in principle be applied.

**A pilot questionnaire will need pre-testing**

Which approach will finally be adopted will depend on pre-tests of a pilot questionnaires that will have to inquire about data availability and national (DRG)-variants for the international mapping. This questionnaire will also have to ask for the case-variants, the reasons (criteria) by which they differ, cost-implications (differences), and overall questions on the coverage of national DRG systems (share of the total inpatient market covered by DRG system; share of coverage of selected indicators of total reimbursement under DRG system; cost-coverage of DRG reimbursement versus extra subsidies and/or other mark-ups, such as for depreciation of investment in systems of dual hospital financing).

**Finally, a message to policy makers: strengthening the links between cost and performance of health care services at all levels of the system (providers, cities, regions), should be at the heart of improving health care at all levels of the system**

Increasing accountability in health care systems and making quality and outcome of care more “predictable” for given resource utilisation and cost, could in fact be seen as the single most important challenge of health policy. Uncertainty in the interplay of performance parameters is no doubt much more than a “statistical” problem. But the “un-predictiveness” of results versus cost (and prices) that currently prevails severely limits the analytical capacity of international comparisons. Establishing more accountability would certainly also help statisticians to do a much better job in international comparisons.
References


DELSA/ELSA/WP1/HCQ(2004)2 Health care quality indicator project: Initial indicator list: Data availability and comparability


Lambie, L., S. Mattke and the Members of the OECD Cardiac Care Panel (2004), Selecting Indicators for the Quality of Cardiac Care at the Health Systems Level in OECD Countries, OECD Health Technical Papers, No.14, OECD, Paris.


Marshall, M., S. Leatherman, S. Mattke and the Members of the OECD Health Promotion, Prevention and Primary Care Panel (2004), Selecting Indicators for the Quality of Health Promotion, Prevention and Primary Care at the Health System Level in OECD Countries, OECD Health Technical Papers, No.16, OECD, Paris.


Annex 1. The Health BASKET project

The primary aim of the European Commission funded project HealthBASKET (2004-2007, DG Research, 6th framework programme) is to develop a methodology which allows comparisons of the costs of individual health services between different EU Member States. Moreover, this project explores the reasons underlying the variations in costs of individual services between countries. “Cost” is the preferred term in this project over “prices”, a term that is reserved for situations where a (quasi-) market of service providers exists.

The HealthBasket project studies a sample of 9 EU Member States (Denmark, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, United Kingdom) representing the various types of European health care systems. This project is organised around the following core tasks:

• Collect and describe how different countries define the services provided within the system by analysing both the structure and contents of benefit “catalogues” (or “baskets”) as well as the process of defining these benefits catalogues;

• Explore the possibilities of building an European taxonomy of benefits, based on that analysis and other relevant classifications, to enable a common language for cost comparisons;

• Review methodologies used to assess costs and prices of services across countries and to identify “best practice” in the analysis of costs at the micro-level with the scope of international comparability;

• Assess costs variations between and within countries, using a selection of “case-vignettes” representing need for care in both inpatient and out-patient settings.

A key aim of the study is to identify what existing possibilities for and limitations to comparison exist, and to recommend the minimum data required for furnishing meaningful international comparisons.

For the project of H-PPPs the first results on the (wide) variations in cost of selected health care interventions are important to understand how close these come to “administrative prices”, such as items on fee-for-service lists, or reimbursements under DRG systems. HealthBasket is the biggest project ever undertaken with these goals in mind. Its total duration is three years, ending in March 2007.
### Annex 2. International Shortlist for Hospital Morbidity Tabulation (ISHMT)

<table>
<thead>
<tr>
<th>Heading</th>
<th>ICD-10 Code</th>
<th>ICD-9 Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases</td>
<td>A00-B99</td>
<td>001-033, 0341-0992, 0995-134, 1360, 1362-139, +042-044 or 2795, 2796 for HIV (varies according to country)</td>
</tr>
<tr>
<td>Intestinal infectious diseases except diarrhoea</td>
<td>A00-A08</td>
<td>001-008</td>
</tr>
<tr>
<td>Diarrhoea and gastroenteritis of presumed infectious origin</td>
<td>A09</td>
<td>009</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>A15-A19, B90</td>
<td>010-018, 137</td>
</tr>
<tr>
<td>Septicaemia</td>
<td>A40-A41</td>
<td>038</td>
</tr>
<tr>
<td>Human immunodeficiency virus [HIV] disease</td>
<td>B20-B24</td>
<td>042-044 or 2795, 2796 (varies according to country)</td>
</tr>
<tr>
<td>Other infectious and parasitic diseases</td>
<td>remainder of A00-B99</td>
<td>remainder of 001-139, except 0340, 0993, 0994, 135, 1361</td>
</tr>
<tr>
<td>Neoplasms</td>
<td>C00-D48</td>
<td>140-239</td>
</tr>
<tr>
<td>Malignant neoplasm of colon, rectum and anus</td>
<td>C18-C21</td>
<td>153, 154</td>
</tr>
<tr>
<td>Malignant neoplasms of trachea, bronchus and lung</td>
<td>C33-C34</td>
<td>162</td>
</tr>
<tr>
<td>Malignant neoplasms of skin</td>
<td>C43-C44</td>
<td>172, 173</td>
</tr>
<tr>
<td>Malignant neoplasm of breast</td>
<td>C50</td>
<td>174, 175</td>
</tr>
<tr>
<td>Malignant neoplasm of uterus</td>
<td>C53-C55</td>
<td>179, 180, 182</td>
</tr>
<tr>
<td>Malignant neoplasm of ovary</td>
<td>C56</td>
<td>1830</td>
</tr>
<tr>
<td>Malignant neoplasm of prostate</td>
<td>C61</td>
<td>185</td>
</tr>
<tr>
<td>Malignant neoplasm of bladder</td>
<td>C67</td>
<td>188</td>
</tr>
<tr>
<td>Other malignant neoplasms</td>
<td>remainder of C00-C97</td>
<td>remainder of 140-208</td>
</tr>
<tr>
<td>Carcinoma in situ</td>
<td>D00-D09</td>
<td>230-234</td>
</tr>
<tr>
<td>Benign neoplasm of colon, rectum and anus</td>
<td>D12</td>
<td>2113, 2114</td>
</tr>
<tr>
<td>Leiomyoma of uterus</td>
<td>D25</td>
<td>218</td>
</tr>
<tr>
<td>Other benign neoplasms and neoplasms of uncertain or unknown behaviour</td>
<td>remainder of D00-D48</td>
<td>remainder of 210-239</td>
</tr>
<tr>
<td>Diseases of the blood and bloodforming organs and certain disorders involving the immune mechanism</td>
<td>D50-D89</td>
<td>135, 2790-2793, 2798, 2799, 280-289</td>
</tr>
<tr>
<td>Anaemias</td>
<td>D50-D64</td>
<td>280-285</td>
</tr>
<tr>
<td>Other diseases of the blood and bloodforming organs and certain disorders involving the immune mechanism</td>
<td>D65-D89</td>
<td>135, 2790-2793, 2798, 2799, 286-289</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases</td>
<td>E00-E90</td>
<td>240-278</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>E10-E14</td>
<td>250</td>
</tr>
<tr>
<td>Other endocrine, nutritional and metabolic diseases</td>
<td>remainder of E00-E90</td>
<td>remainder of 240-278</td>
</tr>
<tr>
<td>Mental and behavioural disorders</td>
<td>F00-F99</td>
<td>290-319</td>
</tr>
<tr>
<td>Dementia</td>
<td>F00-F03</td>
<td>2900-2902, 2904-2909, 2941</td>
</tr>
<tr>
<td>Mental and behavioural disorders due to alcohol</td>
<td>F10</td>
<td>291, 303, 3050</td>
</tr>
<tr>
<td>Mental and behavioural disorders due to use of other psychoactive subst.</td>
<td>F11-F19</td>
<td>292, 2940, 304, 3051-3059</td>
</tr>
<tr>
<td>Schizophrenia, schizotypal and delusional disorders</td>
<td>F20-F29</td>
<td>295, 2970-2973, 2978-2979, 2983-2989</td>
</tr>
<tr>
<td>Mood [affective] disorders</td>
<td>F30-F39</td>
<td>296, 2980, 3004, 3011, 311</td>
</tr>
<tr>
<td>Other mental and behavioural disorders</td>
<td>remainder of F00-F99</td>
<td>remainder of 290-319</td>
</tr>
<tr>
<td>Diseases of the nervous system</td>
<td>G00-G99</td>
<td>320-359, 435</td>
</tr>
<tr>
<td>Alzheimer's disease</td>
<td>G30</td>
<td>3310</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>G35</td>
<td>340</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>G40, G41</td>
<td>345</td>
</tr>
<tr>
<td>Transient cerebral ischaemic attacks and related syndromes</td>
<td>G45</td>
<td>435</td>
</tr>
<tr>
<td>Other diseases of the nervous system</td>
<td>remainder of G00-G99</td>
<td>remainder of 320-359</td>
</tr>
<tr>
<td>Diseases of the eye and adnexa</td>
<td>H00-H59</td>
<td>360-379</td>
</tr>
<tr>
<td>Cataract</td>
<td>H25-H26, H28</td>
<td>366</td>
</tr>
<tr>
<td>Other diseases of the eye and adnexa</td>
<td>remainder of H00-H59</td>
<td>remainder of 360-379</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process</td>
<td>H60-H95</td>
<td>380-389</td>
</tr>
<tr>
<td>Diseases of the circulatory system</td>
<td>I00-I99</td>
<td>390-459 except 435 and 446</td>
</tr>
<tr>
<td>Hypertensive diseases</td>
<td>I10-I15</td>
<td>401-405</td>
</tr>
<tr>
<td>Angina pectoris</td>
<td>I20</td>
<td>413</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>I21-I22</td>
<td>410</td>
</tr>
<tr>
<td>Other ischaemic heart disease</td>
<td>I23-I25</td>
<td>411-412, 414</td>
</tr>
<tr>
<td>Pulmonary heart disease &amp; diseases of pulmonary circulation</td>
<td>I26-I28</td>
<td>415-417</td>
</tr>
<tr>
<td>Conduction disorders and cardiac arrhythmias</td>
<td>I44-I49</td>
<td>426, 427</td>
</tr>
<tr>
<td>Heart failure</td>
<td>I50</td>
<td>428</td>
</tr>
<tr>
<td>Cerebrovascular diseases</td>
<td>I60-I69</td>
<td>430-434, 436-438</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>I70</td>
<td>440</td>
</tr>
<tr>
<td>Varicose veins of lower extremities</td>
<td>I83</td>
<td>454</td>
</tr>
<tr>
<td>Other diseases of the circulatory system</td>
<td>remainder of I00-I99</td>
<td>remainder of 390-459 except 435 and 446</td>
</tr>
<tr>
<td>Diseases of the respiratory system</td>
<td>J00-J99</td>
<td>0340, 460-519</td>
</tr>
<tr>
<td>Acute upper respiratory infections and influenza</td>
<td>J00-J11</td>
<td>0340, 460-465, 487</td>
</tr>
</tbody>
</table>

54
Pneumonia
Other acute lower respiratory infections
Chronic diseases of tonsils and adenoids
Other diseases of upper respiratory tract
Chronic obstructive pulmonary disease and bronchiectasis
Asthma
Other diseases of the respiratory system
Diseases of the digestive system
Disorders of teeth and supporting structures
Other diseases of oral cavity, salivary glands and jaws
Diseases of oesophagus
Pepitic ulcer
Dyspepsia and other diseases of stomach and duodenum
Diseases of appendix
Inguinal hernia
Other abdominal hernia
Crohn's disease and ulcerative colitis
Other noninfective gastroenteritis and colitis
Paralytic ileus and intestinal obstruction without hernia
Diverticular disease of intestine
Diseases of anus and rectum
Other diseases of intestine
Alcoholic liver disease
Other diseases of liver
Cholelithiasis
Other diseases of gall bladder and biliary tract
Diseases of pancreas
Other diseases of the digestive system
Diseases of the skin and subcutaneous tissue
Infections of the skin and subcutaneous tissue
Dermatitis, eczema and papulosquamous disorders
Other diseases of the skin and subcutaneous tissue
Diseases of the musculoskeletal system and connective tissue
Coxarthrosis (arthrosis of hip)
Gonarthrosis (arthrosis of knee)
Internal derangement of knee
Other arthropathies
Systemic connective tissue disorders
Degenerative joint diseases and spondylarthropathies
Intervertebral disc disorders
Dorsalgia
Soft tissue disorders
Other disorders of the musculoskeletal system and connective tissue
Diseases of the genitourinary system
Glomerular and renal tubulo-interstitial diseases
Renal failure
Urolithiasis
Other diseases of the urinary system
Hyperplasia of prostate
Other diseases of male genital organs
Disorders of breast
Inflammatory diseases of female pelvic organs
Menstrual, menopausal and other female genital conditions
Other disorders of the genitourinary system
Pregnancy, childbirth and the puerperium
Medical abortion

Medical abortion
<table>
<thead>
<tr>
<th>Category</th>
<th>Code Range</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other pregnancy with abortive outcome</td>
<td>O00-O03, O05-O08</td>
<td>630-634, 636-639</td>
</tr>
<tr>
<td>Complications of pregnancy predominantly in the antenatal period</td>
<td>O10-O48</td>
<td>640-646, 651-659</td>
</tr>
<tr>
<td>Complications of pregnancy predominantly during labour and delivery</td>
<td>O60-O75</td>
<td>660-668, 6690-6694, 6698, 6699</td>
</tr>
<tr>
<td>Single spontaneous delivery</td>
<td>O80</td>
<td>650</td>
</tr>
<tr>
<td>Other delivery</td>
<td>O81-O84</td>
<td>6695, 6696, 6697</td>
</tr>
<tr>
<td>Complications predominantly related to the puerperium</td>
<td>O85-O92</td>
<td>670-676</td>
</tr>
<tr>
<td>Other obstetric conditions</td>
<td>O95-O99</td>
<td>647, 648</td>
</tr>
<tr>
<td><strong>Certain conditions originating in the perinatal period</strong></td>
<td>P00-P96</td>
<td>760-779</td>
</tr>
<tr>
<td>Disorders related to short gestation and low birth weight</td>
<td>P07</td>
<td>765</td>
</tr>
<tr>
<td>Other conditions originating in the perinatal period</td>
<td>remainder of P00-P96</td>
<td>remainder of 760-779</td>
</tr>
<tr>
<td>Congenital malformations, deformations and chromosomal abnormalities</td>
<td>Q00-Q99</td>
<td>740-759</td>
</tr>
<tr>
<td>Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified</td>
<td>R00-R99</td>
<td>780-799 except 7880, but including 5997</td>
</tr>
<tr>
<td>Pain in throat and chest</td>
<td>R07</td>
<td>7841, 7865</td>
</tr>
<tr>
<td>Abdominal and pelvic pain</td>
<td>R10</td>
<td>7890</td>
</tr>
<tr>
<td>Unknown and unspecified causes of morbidity (incl. those without a diagnosis)</td>
<td>R69</td>
<td>7999</td>
</tr>
<tr>
<td>Other symptoms, signs and abnormal clinical and laboratory findings</td>
<td>remainder of R00-R99</td>
<td>remainder of 780-799 except 7880, but including 5997</td>
</tr>
<tr>
<td><strong>Injury, poisoning and certain other consequences of external causes</strong></td>
<td>S00-T98</td>
<td>800-999</td>
</tr>
<tr>
<td>Intracranial injury</td>
<td>S06</td>
<td>8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854 (Definition includes relevant ICD-9-CM codes.)</td>
</tr>
<tr>
<td>Other injuries to the head</td>
<td>S00-S05, S07-S09</td>
<td>8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925 (Definition includes relevant ICD-9-CM codes.)</td>
</tr>
<tr>
<td>Fracture of forearm</td>
<td>S52</td>
<td>813</td>
</tr>
<tr>
<td>Fracture of femur</td>
<td>S72</td>
<td>820, 821</td>
</tr>
<tr>
<td>Fracture of lower leg, including ankle</td>
<td>S82</td>
<td>823, 824</td>
</tr>
<tr>
<td>Burns and corrosions</td>
<td>T20-T32</td>
<td>940-949</td>
</tr>
<tr>
<td>Poisonings by drugs, medicaments and biological substances and toxic effects of substances chiefly nonmedicinal as to source</td>
<td>T36-T65</td>
<td>960-989</td>
</tr>
<tr>
<td>Complications of surgical and medical care, not elsewhere classified</td>
<td>T80-T88</td>
<td>996-999</td>
</tr>
<tr>
<td>Sequelae of injuries, of poisoning and of other consequences of external causes</td>
<td>T90-T98</td>
<td>905-909</td>
</tr>
<tr>
<td>Other and unspecified effects of external causes</td>
<td>remainder of S00-T98</td>
<td>990-995</td>
</tr>
<tr>
<td><strong>Factors influencing health status and contact with health services</strong></td>
<td>Z00-Z99</td>
<td>V01-V82</td>
</tr>
<tr>
<td>Medical observation and evaluation for suspected diseases and conditions</td>
<td>Z03</td>
<td>V71</td>
</tr>
<tr>
<td>Contraceptive management</td>
<td>Z30</td>
<td>V25</td>
</tr>
<tr>
<td>Liveborn infants according to place of birth (&quot;healthy newborn babies&quot;)</td>
<td>Z38</td>
<td>V30-V39</td>
</tr>
<tr>
<td>Other medical care (including radiotherapy and chemotherapy sessions)</td>
<td>Z51</td>
<td>V071, V58</td>
</tr>
<tr>
<td>Other factors influencing health status and contact with health services</td>
<td>remainder of Z00-Z99</td>
<td>remainder of V01-V82</td>
</tr>
<tr>
<td><strong>All causes</strong></td>
<td>A00-Z99 (excluding V, W, X and Y codes)</td>
<td>001-V82 (excluding E800-E999)</td>
</tr>
</tbody>
</table>

56